Pharmafile Logo

medicines access

- PMLiVE

Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’

Sales grew by 19% in the second quarter as key products begin to recover from the impact of the pandemic

- PMLiVE

GSK beats expectations thanks to strong vaccine sales in Q2

GSK's vaccine business was up by 39% to £1.6bn thanks to the strong growth (46%) of its meningitis vaccine

- PMLiVE

AZ raises full-year guidance after completing Alexion acquisition in Q2

Total revenue was up by 31% to $8.2bn and also increased by 24% to $15.2bn for the half year

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand

The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...

Impetus Digital

Employee wellbeing in creative agencies: three tips to get you started

Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration

Fox&Cat

- PMLiVE

J&J and Pfizer quietly resolve Remicade biosimilar lawsuit

In 2017, Pfizer filed a lawsuit against J&J alleging that the company undertook anticompetitive practices in a bid to protect Remicade

- PMLiVE

AZ’s PNH therapy Ultomiris wins EU backing to expand use for children

The positive recommendation is based on interim results from a phase 3 trial

- PMLiVE

One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants

New real-world data from Canada shows vaccine efficacy was lower against milder symptomatic disease with one dose

- PMLiVE

J&J, distributors reach $26bn settlement to address the opioid crisis in the US

The proposed agreement would resolve claims of both states and local governments in the US

- PMLiVE

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

Swiss pharma company also provided key updates on a number of drug candidates in its pipeline

- PMLiVE

EMA begins rolling review of Sanofi, GSK’s COVID-19 vaccine

Rolling review launched based on preliminary results from lab studies and early clinical studies

- PMLiVE

AZ licenses pneumonia mAb to Aridis Pharmaceuticals for $11m upfront

The candidate – suvratoxumab – is ready for phase 3 clinical evaluation for the prevention of pneumonia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links